New drug ZGGS34 targets Hard-to-Treat cancers in early trial
NCT ID NCT07258121
First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 17 times
Summary
This study tests a new drug called ZGGS34 in about 400 people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, checking if the drug works alone or with chemotherapy. Only people whose tumors have a specific marker (MUC17) can join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.